Graham Capital Management
RLMD icon

Graham Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Graham Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,493
Closed -$93.9K – 1463
2026
Q1 		$93.9K Sell
13,493
-12,115
-47% -$57.3K ﹤0.01% 1051
2025
Q4 		$124K Buy
+25,608
New +$85.8K ﹤0.01% 1125
2023
Q1 		– Sell
-26,258
Closed -$91.6K – 1290
2022
Q4 		$91.6K Buy
+26,258
New +$231K ﹤0.01% 999

Other funds holding RLMD

Jupiter Topco
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Graham Capital Management's RLMD Position: Q2 2026 in Review

Graham Capital Management sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 13,493 shares — an estimated $93.9K sold.

Graham Capital Management first reported a position in RLMD in Q4 2022 and held it in 3 quarters. The position peaked at $124K in Q4 2025. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Graham Capital Management reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 13,493 Relmada Therapeutics shares in Q2 2026, an estimated $93.9K.
  • Graham Capital Management first reported a position in Relmada Therapeutics in Q4 2022 and held it in 3 quarters.
  • Graham Capital Management's Relmada Therapeutics position peaked at $124K in Q4 2025.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.